130 related articles for article (PubMed ID: 26953280)
1. Insulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus.
Clements JN; Bello L
Am J Health Syst Pharm; 2016 Mar; 73(6):359-66. PubMed ID: 26953280
[TBL] [Abstract][Full Text] [Related]
2. Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus.
Blair HA; Keating GM
Drugs; 2016 Mar; 76(3):363-74. PubMed ID: 26821280
[TBL] [Abstract][Full Text] [Related]
3. Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL.
Clements JN; Threatt T; Ward E; Shealy KM
Clin Pharmacokinet; 2017 May; 56(5):449-458. PubMed ID: 27699623
[TBL] [Abstract][Full Text] [Related]
4. A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine.
Dailey G; Lavernia F
Diabetes Obes Metab; 2015 Dec; 17(12):1107-14. PubMed ID: 26139151
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance.
Owens DR
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):977-87. PubMed ID: 27453980
[TBL] [Abstract][Full Text] [Related]
6. [New generation of insulins: glargine U300. Summary of clinical evidence].
Musso C; Capurro L; Mingote E; Forti L; Guaita MS
Medicina (B Aires); 2019; 79(4):241-250. PubMed ID: 31487242
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes.
Hurren KM; O'Neill JL
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1521-1526. PubMed ID: 27710135
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature.
Vargas-Uricoechea H
J Diabetes Res; 2018; 2018():2052101. PubMed ID: 29619381
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
[TBL] [Abstract][Full Text] [Related]
10. Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension).
Terauchi Y; Koyama M; Cheng X; Sumi M; Riddle MC; Bolli GB; Hirose T;
Diabetes Metab; 2017 Oct; 43(5):446-452. PubMed ID: 28433560
[TBL] [Abstract][Full Text] [Related]
11. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
Pollock RF; Tikkanen CK
J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
[TBL] [Abstract][Full Text] [Related]
13. U300, a novel long-acting insulin formulation.
Sutton G; Minguet J; Ferrero C; Bramlage P
Expert Opin Biol Ther; 2014 Dec; 14(12):1849-60. PubMed ID: 25311556
[TBL] [Abstract][Full Text] [Related]
14. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies.
Duckworth W; Davis SN
J Diabetes Complications; 2007; 21(3):196-204. PubMed ID: 17493554
[TBL] [Abstract][Full Text] [Related]
15. The role of Toujeo®, insulin glargine U-300, in the treatment of diabetes mellitus.
Brown MA; Davis CS; Fleming LW; Fleming JW
J Am Assoc Nurse Pract; 2016 Sep; 28(9):503-9. PubMed ID: 26990724
[TBL] [Abstract][Full Text] [Related]
16. [Basal insulin glargine using a basal-bolus regimen in a common clinical practice: observational, non-interventional, multicenter, national project LINDA (Lantus in daily practice - safety and efficacy in basal bolus regimen)].
Zďarská DJ; Brož J; Křivská B; Rušavý Z; Kvapil M
Vnitr Lek; 2014 Sep; 60(9):712-9. PubMed ID: 25294758
[TBL] [Abstract][Full Text] [Related]
17. Insulin glargine: a new basal insulin.
Levien TL; Baker DE; White JR; Campbell RK
Ann Pharmacother; 2002 Jun; 36(6):1019-27. PubMed ID: 12022906
[TBL] [Abstract][Full Text] [Related]
18. Insulin glargine 300 units/mL: a guide for healthcare professionals involved in the management of diabetes.
Strong J; Kruger D; Novak L
Curr Med Res Opin; 2017 Apr; 33(4):785-793. PubMed ID: 28132529
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir.
Bryant GA; McDanel DL; Horner KE; Farris KB; Newkirk EN
Pharmacotherapy; 2013 Jan; 33(1):56-62. PubMed ID: 23307546
[TBL] [Abstract][Full Text] [Related]
20. Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.
Bolli GB; Riddle MC; Bergenstal RM; Wardecki M; Goyeau H; Home PD;
Diabetes Metab; 2017 Sep; 43(4):351-358. PubMed ID: 28622950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
